Your browser doesn't support javascript.
loading
Development of red blood cell-derived extracellular particles as a biocompatible nanocarrier of microRNA-204 (REP-204) to harness anti-neuroblastoma effect.
Chiangjong, Wararat; Panachan, Jirawan; Keadsanti, Sujitra; Newburg, David S; Morrow, Ardythe L; Hongeng, Suradej; Chutipongtanate, Somchai.
Afiliación
  • Chiangjong W; Pediatric Translational Research Unit, Division of Evidence-based Pediatrics and Research, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand. Electronic address: wararat.chi@mahidol.ac.th.
  • Panachan J; Division of Hematology and Oncology, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand.
  • Keadsanti S; Center of Excellence for Antibody Research, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand.
  • Newburg DS; MILCH and Novel Therapeutics Lab, Division of Epidemiology, Department of Environmental and Public Health Sciences, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, United States.
  • Morrow AL; MILCH and Novel Therapeutics Lab, Division of Epidemiology, Department of Environmental and Public Health Sciences, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, United States; Division of Infectious Diseases, Department of Pediatrics, Cincinnati Children's Hospital Medical C
  • Hongeng S; Division of Hematology and Oncology, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand.
  • Chutipongtanate S; MILCH and Novel Therapeutics Lab, Division of Epidemiology, Department of Environmental and Public Health Sciences, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, United States; Extracellular Vesicle Working Group, University of Cincinnati College of Medicine, Cincinnati, Ohio
Nanomedicine ; 60: 102760, 2024 Aug.
Article en En | MEDLINE | ID: mdl-38852882
ABSTRACT
Neuroblastoma (NB) is the most common extracranial solid tumor in the pediatric population with a high degree of heterogeneity in clinical outcomes. Upregulation of the tumor suppressor miR-204 in neuroblastoma is associated with good prognosis. Although miR-204 has been recognized as a potential therapeutic candidate, its delivery is unavailable. We hypothesized that REP-204, the red blood cell-derived extracellular particles (REP) with miR-204 loading, can suppress neuroblastoma cells in vitro. After miR-204 loading by electroporation, REP-204, but not REP carriers, inhibited the viability, migration, and 3D spheroid growth of neuroblastoma cells regardless of MYCN amplification status. SWATH-proteomics revealed that REP-204 treatment may trigger a negative regulation of mRNA splicing by the spliceosome, suppression of amino acid metabolism and protein production, and prevent SLIT/ROBO signaling-mediated cell migration, to halt neuroblastoma tumor growth and metastasis. The therapeutic efficacy of REP-204 should be further investigated in preclinical models and clinical studies.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: MicroARNs / Neuroblastoma Límite: Humans Idioma: En Revista: Nanomedicine Asunto de la revista: BIOTECNOLOGIA Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: MicroARNs / Neuroblastoma Límite: Humans Idioma: En Revista: Nanomedicine Asunto de la revista: BIOTECNOLOGIA Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos